CA2465565A1 - Compositions pharmaceutiques d'atorvastatine - Google Patents
Compositions pharmaceutiques d'atorvastatine Download PDFInfo
- Publication number
- CA2465565A1 CA2465565A1 CA002465565A CA2465565A CA2465565A1 CA 2465565 A1 CA2465565 A1 CA 2465565A1 CA 002465565 A CA002465565 A CA 002465565A CA 2465565 A CA2465565 A CA 2465565A CA 2465565 A1 CA2465565 A1 CA 2465565A1
- Authority
- CA
- Canada
- Prior art keywords
- atorvastatin
- wet
- composition
- optionally
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47811903P | 2003-06-12 | 2003-06-12 | |
US60/478,119 | 2003-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2465565A1 true CA2465565A1 (fr) | 2004-12-12 |
Family
ID=33551806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002465565A Abandoned CA2465565A1 (fr) | 2003-06-12 | 2004-04-29 | Compositions pharmaceutiques d'atorvastatine |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1635814A1 (fr) |
JP (1) | JP2006527260A (fr) |
KR (1) | KR100814218B1 (fr) |
CN (1) | CN100434069C (fr) |
AR (1) | AR044774A1 (fr) |
AU (1) | AU2004246868B2 (fr) |
BR (1) | BRPI0411344A (fr) |
CA (1) | CA2465565A1 (fr) |
CO (1) | CO5650230A2 (fr) |
MX (1) | MXPA05013281A (fr) |
NO (1) | NO20060022L (fr) |
NZ (1) | NZ543337A (fr) |
RU (1) | RU2332211C2 (fr) |
TW (1) | TW200503690A (fr) |
WO (1) | WO2004110431A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE40667E1 (en) | 1989-07-21 | 2009-03-17 | Warner-Lambert Company Llc | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
CA2691956A1 (fr) * | 2007-06-25 | 2008-12-31 | Pharmathen S.A. | Formulation pharmaceutique amelioree contenant un inhibiteur de la hmg-coa reductase et son procede de preparation |
US8414958B2 (en) * | 2008-02-27 | 2013-04-09 | Thommen Medical Ag | Implant and method for the manufacture thereof |
AU2009292615B2 (en) * | 2008-09-17 | 2015-12-03 | Mylan Inc. | Granulates, process for preparing them and pharmaceutical products containing them |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
IN2014CN04119A (fr) | 2011-11-15 | 2015-07-10 | Reddys Lab Ltd Dr | |
CN104069078B (zh) * | 2014-05-22 | 2019-06-11 | 西藏九瑞健康股份有限公司 | 阿托伐他汀钙药物组合物及其制备方法 |
EP3172209B1 (fr) | 2014-07-25 | 2020-12-02 | Novartis AG | Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide |
KR101658350B1 (ko) * | 2015-02-06 | 2016-09-30 | 경성대학교 산학협력단 | 고지혈증 치료에 유용한 약학 조성물 |
WO2016145132A1 (fr) * | 2015-03-12 | 2016-09-15 | Fmc Corporation | Dispersions solides |
CN109152787A (zh) | 2016-03-31 | 2019-01-04 | 英特塞普特医药品公司 | 具有优越的溶出性的口服制剂 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0680320B1 (fr) * | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Formulation ci-981, orale, stable et son procede de preparation |
JPH06242003A (ja) * | 1993-02-12 | 1994-09-02 | Nkk Corp | 鉄鋼中のアルミナの粒度測定方法 |
JP3014040B2 (ja) * | 1996-10-30 | 2000-02-28 | 信久 川野 | 食物繊維パン及びその製造法 |
ES2401598T3 (es) * | 2000-04-10 | 2013-04-22 | Teva Pharmaceutical Industries, Ltd. | Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
EP1226818A1 (fr) * | 2001-01-26 | 2002-07-31 | Pfizer Products Inc. | Formulation pharmaceutique présentant des propriétés de cohesion et de compressibilité améliorées |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
-
2004
- 2004-04-29 CA CA002465565A patent/CA2465565A1/fr not_active Abandoned
- 2004-06-01 BR BRPI0411344-6A patent/BRPI0411344A/pt not_active IP Right Cessation
- 2004-06-01 MX MXPA05013281A patent/MXPA05013281A/es not_active Application Discontinuation
- 2004-06-01 EP EP04735614A patent/EP1635814A1/fr not_active Withdrawn
- 2004-06-01 NZ NZ543337A patent/NZ543337A/en unknown
- 2004-06-01 AU AU2004246868A patent/AU2004246868B2/en not_active Ceased
- 2004-06-01 KR KR1020057023669A patent/KR100814218B1/ko not_active IP Right Cessation
- 2004-06-01 WO PCT/IB2004/001862 patent/WO2004110431A1/fr active Application Filing
- 2004-06-01 RU RU2005136745/15A patent/RU2332211C2/ru not_active IP Right Cessation
- 2004-06-01 CN CNB2004800163910A patent/CN100434069C/zh not_active Expired - Fee Related
- 2004-06-01 JP JP2006516512A patent/JP2006527260A/ja active Pending
- 2004-06-10 AR ARP040102008A patent/AR044774A1/es unknown
- 2004-06-11 TW TW093116894A patent/TW200503690A/zh unknown
-
2005
- 2005-12-09 CO CO05124741A patent/CO5650230A2/es not_active Application Discontinuation
-
2006
- 2006-01-03 NO NO20060022A patent/NO20060022L/no not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE40667E1 (en) | 1989-07-21 | 2009-03-17 | Warner-Lambert Company Llc | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1805741A (zh) | 2006-07-19 |
NZ543337A (en) | 2008-03-28 |
JP2006527260A (ja) | 2006-11-30 |
KR100814218B1 (ko) | 2008-03-17 |
NO20060022L (no) | 2006-01-03 |
TW200503690A (en) | 2005-02-01 |
BRPI0411344A (pt) | 2006-07-11 |
AR044774A1 (es) | 2005-10-05 |
AU2004246868B2 (en) | 2008-01-17 |
CN100434069C (zh) | 2008-11-19 |
KR20060020666A (ko) | 2006-03-06 |
CO5650230A2 (es) | 2006-06-30 |
RU2332211C2 (ru) | 2008-08-27 |
RU2005136745A (ru) | 2006-07-27 |
EP1635814A1 (fr) | 2006-03-22 |
AU2004246868A1 (en) | 2004-12-23 |
WO2004110431A1 (fr) | 2004-12-23 |
MXPA05013281A (es) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7790197B2 (en) | Pharmaceutical compositions of atorvastatin | |
US20090226510A1 (en) | Pharmaceutical compositions of atorvastatin | |
RU2293555C2 (ru) | Аторвастатин кальций в фармацевтической форме, его композиция и фармацевтическая рецептура, содержащая аторвастатин кальций | |
US20090196932A1 (en) | Pharmaceutical compositions of atorvastatin | |
US20090088465A1 (en) | Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same | |
WO2007103453A1 (fr) | Compositions à base d'ézétimibe | |
AU2004246868B2 (en) | Stable compositions of atorvastatin prepared with wet granulation | |
KR100760112B1 (ko) | 아토르바스타틴의 제약 조성물 | |
ES2239119T3 (es) | Preparacion de principio activo de ibuprofeno. | |
KR101171375B1 (ko) | 난용성 약물을 함유하는 경구 제형 | |
AU2008200759A1 (en) | Stable compositions of atorvastatin prepared with wet granulation | |
WO2013072770A2 (fr) | Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |